PROF

MKT CAP:$212M

Profound Medical Corp.

Market Cap

$212M

Healthcare·Medical - Devices·🇨🇦 Canada·NASDAQ

Healthcare·Medical - Devices·🇨🇦·NASDAQ

Stock Price

$6.96-$0.70 (-9.14%)

Apr 21, 2026

Company Details

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pa...

CEO

Arun Swarup Menawat

IPO Date

Oct 29, 2019

Website

www.profoundmedical.com

Key Metrics TTM

Revenue

$12M

+101.6% YoY

Net Income

-$32M

EPS (Diluted)

-$1.27

Free Cash Flow

-$29M

Revenue / Share

$0.38

Gross Margin

69.7%

Operating Margin

-309.8%

Net Margin

-278.7%

FCF Margin

-247.4%

P/S

18.4x

P/E

—

Earnings Reports

Q4 2025

May 14, 2026

PENDING

FY 2025

Mar 5, 2026

$16MEPS $1.41

Q3 2025

Nov 13, 2025

$5MEPS -$0.37

Q1 2025

May 8, 2025

$3M+82.1%EPS -$0.36

Q2 2024

Mar 7, 2025

$2M+39.4%EPS -$0.28

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 16	$0	$0	-$4M
Q1 17	$324.1K	$153.6K	-$3M
Q4 17	$1M	$472.0K	-$3M
Q1 18	$213.0K	$82.2K	-$3M
Q4 18	$890.9K	$274.9K	-$2M
Q1 19	$807.7K	$515.8K	-$1M
Q4 19	$2M	$910.1K	$3M
Q1 20	$847.7K	$323.0K	-$4M
Q2 20	$749.8K	$304.0K	-$3M
Q3 20	$2M	$1M	-$4M
Q2 23	$2M	$1M	$6M
Q3 23	$2M	$1M	-$7M
Q1 24	$1M	$866.0K	-$8M
Q2 24	$2M	$1M	-$8M
Q1 25	$3M	$2M	-$11M
Q3 25	$5M	$4M	-$9M

Valuation

Quarter	P/S	P/E
Q4 16	—	—
Q1 17	654.4x	—
Q4 17	151.6x	—
Q1 18	131.6x	—
Q4 18	84.8x	—
Q1 19	71.0x	—
Q4 19	60.7x	—
Q1 20	51.4x	—
Q2 20	53.2x	—
Q3 20	44.0x	—
Q2 23	43.9x	—
Q3 23	37.1x	—
Q1 24	33.1x	—
Q2 24	30.3x	—
Q1 25	26.4x	—
Q3 25	18.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 16	-$2M	-$3M
Q1 17	-$2M	-$2M
Q4 17	-$3M	-$3M
Q1 18	-$2M	-$2M
Q4 18	-$2M	-$2M
Q1 19	-$2M	-$2M
Q4 19	-$4M	-$4M
Q1 20	-$5M	-$5M
Q2 20	-$1M	-$1M
Q3 20	-$3M	-$3M
Q2 23	-$5M	-$5M
Q3 23	-$4M	-$4M
Q1 24	-$5M	-$5M
Q2 24	-$6M	-$6M
Q1 25	-$8M	-$8M
Q3 25	-$9M	-$9M

Capital Expenditures

Quarter	CapEx
Q4 16	$51.5K
Q1 17	$34.2K
Q4 17	$5.5K
Q1 18	$0
Q4 18	$0
Q1 19	$0
Q4 19	$1.9K
Q1 20	$0
Q2 20	$0
Q3 20	$0
Q2 23	$0
Q3 23	$0
Q1 24	$0
Q2 24	$0
Q1 25	$0
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 17	—	+61.0%
Q1 18	—	+12.9%
Q4 18	—	-14.7%
Q1 19	+149.2%	-27.2%
Q4 19	+47.4%	-136.2%
Q1 20	+298.1%	+55.8%
Q2 20	-15.8%	+20.6%
Q3 20	+102.5%	+134.8%
Q2 23	+1.1%	-214.9%
Q3 23	+103.8%	+88.0%
Q1 24	+91.9%	+156.7%
Q2 24	+36.5%	+86.8%
Q1 25	+63.6%	+385.2%
Q3 25	+202.7%	+69.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 16	$266.1K	—
Q1 17	$55.1K	17.0%
Q4 17	$204.4K	19.0%
Q1 18	$136.4K	64.1%
Q4 18	$156.6K	17.6%
Q1 19	$39.8K	4.9%
Q4 19	$358.1K	22.6%
Q1 20	$331.8K	39.1%
Q2 20	$466.2K	62.2%
Q3 20	$714.7K	43.7%
Q2 23	$842.0K	52.6%
Q3 23	$727.0K	42.1%
Q1 24	$767.0K	53.3%
Q2 24	$768.0K	34.4%
Q1 25	$989.0K	37.7%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 16	$1M	$1M	—	—
Q1 17	$1M	$612.7K	$630.5K	—
Q4 17	$1M	$810.9K	$660.6K	—
Q1 18	$1M	$737.5K	$535.8K	—
Q4 18	$1M	$570.8K	$523.1K	—
Q1 19	$1M	$828.7K	—	—
Q4 19	$2M	$1M	$732.6K	—
Q1 20	$2M	$2M	$681.8K	—
Q2 20	$1M	$1M	$725.7K	—
Q3 20	$3M	$1M	$866.7K	—
Q2 23	$3M	$2M	$2M	—
Q3 23	$3M	$2M	$2M	—
Q1 24	$4M	$2M	$2M	—
Q2 24	$4M	—	—	$5M
Q1 25	$5M	—	—	$8M
Q3 25	$5M	$7M	—	—

Revenue Segments

Quarter	Capital Equipment	Recurring - Non-Capital
Q1 25	$820.0K	$2M
Q3 25	$1M	$4M

Revenue by Geography

Quarter	California	Delaware	United States
Q1 25	$852.0K	$226.0K	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$60M	$0	$60M
Q2 22	$53M	$0	$53M
Q3 22	$46M	$0	$46M
Q4 22	$46M	$0	$46M
Q1 23	$43M	$0	$43M
Q2 23	$39M	$0	$39M
Q3 23	$33M	$0	$33M
Q4 23	$35M	$0	$35M
Q1 24	$56M	$0	$56M
Q2 24	$47M	$0	$47M
Q3 24	$27M	$0	$27M
Q4 24	$55M	$0	$55M
Q1 25	$46M	$0	$46M
Q2 25	$35M	$0	$35M
Q3 25	$25M	$0	$25M
Q4 25	$82M	$0	$82M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 16	6M	+40.1%	—
Q1 17	6M	0.0%	—
Q4 17	8M	+39.8%	+95.9%
Q1 18	8M	0.0%	+95.9%
Q4 18	11M	+39.7%	+95.3%
Q1 19	11M	+0.0%	+95.3%
Q4 19	15M	+35.6%	+89.5%
Q1 20	15M	0.0%	+89.5%
Q2 20	16M	+9.8%	+49.0%
Q3 20	19M	+16.2%	+73.1%
Q2 23	21M	+13.1%	+44.4%
Q3 23	21M	+1.1%	+46.0%
Q1 24	24M	+11.4%	+48.1%
Q2 24	24M	+2.5%	+30.6%
Q1 25	30M	+22.9%	+41.9%
Q3 25	30M	+0.2%	+40.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 16	—	—
Q1 17	—	—
Q4 17	—	—
Q1 18	—	—
Q4 18	—	—
Q1 19	—	—
Q4 19	—	—
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q2 23	—	—
Q3 23	—	—
Q1 24	—	—
Q2 24	—	—
Q1 25	$328	8K
Q3 25	$654	8K

Revenue / Employee